Tags

Type your tag names separated by a space and hit enter

Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia.
Hum Psychopharmacol. 2009 Oct; 24(7):565-73.HP

Abstract

OBJECTIVE

To investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (AAPs) to long-acting injectable risperidone (LAIR) in patients with schizophrenia.

METHODS

Thirty-six patients with schizophrenia treated with oral AAPs participated in this open-label, 26-week study. Cognitive functions were measured at baseline and at 12 and 26 weeks. The secondary outcome measures included the Positive and Negative Syndrome Scale (PANSS), Social and Occupational Functioning Assessment Scale (SOFAS), Scale for Unawareness of Mental Disorder (SUMD), and measurements for extrapyramidal symptoms.

RESULTS

Significant improvements in cognitive function were observed in the backward Digit Span Test, Verbal Learning Test, Wisconsin Card Sorting Test, correct responses on the Continuous Performance Test, and Trail Making Test part B following a switch to LAIR. Scores on the PANSS, SOFAS, SUMD, and the Simpson-Angus Rating Scale also improved significantly. Most improvements in neurocognitive function were not correlated with clinical measures. Weight gain and hyperprolactinemia were the most common adverse events.

CONCLUSIONS

Switching from oral AAPs to LAIR improved cognitive function including vigilance, verbal learning and memory, executive function, sustained attention, and visuomotor speed in patients with schizophrenia. It was also effective for improving psychotic symptoms, social functioning, and insight.

Authors+Show Affiliations

Department of Psychiatry, Chonnam National University Medical School and Clinical Trial Center, Chonnam National University Hospital, Gwangju, Republic of Korea.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19790174

Citation

Kim, Sung-Wan, et al. "Effects of Switching to Long-acting Injectable Risperidone From Oral Atypical Antipsychotics On Cognitive Function in Patients With Schizophrenia." Human Psychopharmacology, vol. 24, no. 7, 2009, pp. 565-73.
Kim SW, Shin IS, Kim JM, et al. Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. Hum Psychopharmacol. 2009;24(7):565-73.
Kim, S. W., Shin, I. S., Kim, J. M., Lee, S. H., Lee, Y. H., Yang, S. J., & Yoon, J. S. (2009). Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. Human Psychopharmacology, 24(7), 565-73. https://doi.org/10.1002/hup.1057
Kim SW, et al. Effects of Switching to Long-acting Injectable Risperidone From Oral Atypical Antipsychotics On Cognitive Function in Patients With Schizophrenia. Hum Psychopharmacol. 2009;24(7):565-73. PubMed PMID: 19790174.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of switching to long-acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia. AU - Kim,Sung-Wan, AU - Shin,Il-Seon, AU - Kim,Jae-Min, AU - Lee,Seung-Hyun, AU - Lee,Yo-Han, AU - Yang,Su-Jin, AU - Yoon,Jin-Sang, PY - 2009/10/1/entrez PY - 2009/10/1/pubmed PY - 2009/12/16/medline SP - 565 EP - 73 JF - Human psychopharmacology JO - Hum Psychopharmacol VL - 24 IS - 7 N2 - OBJECTIVE: To investigate changes in cognitive function and clinical features following a switch from oral atypical antipsychotics (AAPs) to long-acting injectable risperidone (LAIR) in patients with schizophrenia. METHODS: Thirty-six patients with schizophrenia treated with oral AAPs participated in this open-label, 26-week study. Cognitive functions were measured at baseline and at 12 and 26 weeks. The secondary outcome measures included the Positive and Negative Syndrome Scale (PANSS), Social and Occupational Functioning Assessment Scale (SOFAS), Scale for Unawareness of Mental Disorder (SUMD), and measurements for extrapyramidal symptoms. RESULTS: Significant improvements in cognitive function were observed in the backward Digit Span Test, Verbal Learning Test, Wisconsin Card Sorting Test, correct responses on the Continuous Performance Test, and Trail Making Test part B following a switch to LAIR. Scores on the PANSS, SOFAS, SUMD, and the Simpson-Angus Rating Scale also improved significantly. Most improvements in neurocognitive function were not correlated with clinical measures. Weight gain and hyperprolactinemia were the most common adverse events. CONCLUSIONS: Switching from oral AAPs to LAIR improved cognitive function including vigilance, verbal learning and memory, executive function, sustained attention, and visuomotor speed in patients with schizophrenia. It was also effective for improving psychotic symptoms, social functioning, and insight. SN - 1099-1077 UR - https://www.unboundmedicine.com/medline/citation/19790174/Effects_of_switching_to_long_acting_injectable_risperidone_from_oral_atypical_antipsychotics_on_cognitive_function_in_patients_with_schizophrenia_ L2 - https://doi.org/10.1002/hup.1057 DB - PRIME DP - Unbound Medicine ER -